BioElectronics Corporation Enters into Distribution Agreement for RecoveryRx in Spain with PRIM Group

BioElectronics Corporation

FREDERICK, MD, April 06, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL, a developer of medical device products, announced today that the Company has entered into a distribution agreement with the in Madrid/Spain based PRIM Group (www.prim.es) for the distribution of its RecoveryRx device throughout Spain.

“PRIM Group in Spain serves as the perfect hub to successfully commercialize RecoveryRx in an important market in Europe,” said Kelly Whelan, President of BioElectronics.

“Our goal is to continue to grow our network of qualified distributors with knowledgeable sales and support staff in close proximity to our customers,” added Erin Sanders, manager of international sales at BioElectronics Corporation.

PRIM Group is expected to provide sales, marketing and distribution services for RecoveryRx throughout Spain. The RecoveryRx medical device is designed to relieve postoperative pain without medication. RecoveryRx is a single-use device designed to provide 720 hours of therapy. RecoveryRx is both FDA cleared and CE marked.

About the PRIM Group: PRIM is a Spanish limited company, listed on the stock exchange since 1985, which represents added value for the healthcare system. PRIM designs, manufactures, markets, installs and services products and equipment that provide advanced solutions. PRIM provides a comprehensive ongoing service through its headquarters, two factories, seven regional offices, four warehouses and six orthopedic clinics. It develops its main activity in hospitals, clinics, health centers, health insurance, orthopedics, individuals, pedicure centers, pharmacies and medical societies.

About bioelectronics: BioElectronics Corporation is a leading provider of non-invasive electroceuticals and manufacturer of industry-leading, single-use, drug-free pain management devices for the over-the-counter treatment of back pain and other musculoskeletal conditions; RecoveryRx® devices for post-operative pain and wound care. Visit http://www.bielcorp.com for more information

The story goes on

Certain information in this email contains “forward-looking information,” including “forward-looking financial information” and “financial outlook” under applicable securities laws (collectively referred to herein as “forward-looking statements”). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, (i) the Company’s projected financial performance; (ii) completion and use of proceeds from the sale of the Shares offered hereunder; (iii) the anticipated development of the Company’s businesses, projects and joint ventures; (iv) executing the company’s vision and growth strategy, including in relation to future M&A activities and global growth; (v) sources and availability of third party funding for the Company’s projects; (vi) completion of the Company’s projects currently underway, under development or otherwise contemplated; (vii) extending the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to enable prospective investors to understand management’s beliefs and opinions regarding the future so that they can use those beliefs and opinions as a factor in evaluating an investment.

These statements are not guarantees of future performance and no undue reliance should be placed on them. Such forward-looking statements inherently involve known and unknown risks and uncertainties that could cause actual performance and financial results in future periods to differ materially from the projections of future performance or results expressed or implied by such forward-looking statements.

Although the forward-looking statements contained in this e-mail are based on reasonable assumptions made by the Company’s management, there can be no assurance that any forward-looking statements will prove to be correct, as actual results and future events could differ materially from those anticipated with such statements. The Company undertakes no obligation to update any forward-looking statement if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on any forward-looking statements.

Contact: Paul Knopick

[email protected]

949.697.1323

>